Compare NEN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
| Metric | NEN | SGMT |
|---|---|---|
| Founded | 1977 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 169.4M |
| IPO Year | 1995 | 2021 |
| Metric | NEN | SGMT |
|---|---|---|
| Price | $59.55 | $7.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 653.0 | ★ 781.4K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,196,544.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | ★ 10.76 | N/A |
| 52 Week Low | $56.00 | $4.50 |
| 52 Week High | $74.00 | $11.41 |
| Indicator | NEN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 55.64 |
| Support Level | $56.83 | $6.26 |
| Resistance Level | $60.90 | $7.20 |
| Average True Range (ATR) | 0.81 | 0.33 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 60.29 | 76.82 |
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.